CPT code 38211 represents specialized processing of hematopoietic progenitor cells (HPCs) using enrichment and depletion techniques to remove tumor cells prior to transplantation. This code is nationally relevant due to growing use of autologous and allogeneic cellular therapies, where minimizing tumor reinfusion is clinically important for patient safety and graft integrity. The procedure is typically performed in hospital or specialized cellular therapy laboratories and is associated with advanced laboratory workflows and quality controls.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and coding intent, payor coverage considerations, and operational benchmarks where available. The publication also summarizes typical sites of service and the service type to aid billing and revenue cycle teams.

This report provides national-level guidance on coding semantics and clinical purpose, highlights common payer coverage patterns, and points to policy and billing topics readers should review when managing claims for complex cellular therapy processing. Data not available in the input are clearly identified where applicable.